文章名稱引用次數

• Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017161
• Association between insulin resistance and the development of cardiovascular disease110
• SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart53
• Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies42
• Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis38
• The selective peroxisome proliferator-activated receptor alpha modulator (SPPARM) paradigm: conceptual framework and therapeutic potential: A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation36
• Class effects of SGLT2 inhibitors on cardiorenal outcomes34
• Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure34
• SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial33
• Diabetes, cardiovascular disease and the microcirculation33